Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C13H17N5O2S |
| Molecular Weight | 307.371 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCC1=NC(NS(=O)(=O)C2=CC=C(N)C=C2)=NC(CC)=N1
InChI
InChIKey=ZQMQGBHQZZQTJE-UHFFFAOYSA-N
InChI=1S/C13H17N5O2S/c1-3-11-15-12(4-2)17-13(16-11)18-21(19,20)10-7-5-9(14)6-8-10/h5-8H,3-4,14H2,1-2H3,(H,15,16,17,18)
| Molecular Formula | C13H17N5O2S |
| Molecular Weight | 307.371 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Sulfasymazine is a sulfanilamide derivative patented by American Cyanamid Co. as antibacterial agents for Staphylococcus and Streptococcus infections. In preclinical models, Sulfasymazine shows activity on a dosage basis ranged from 2- to 10-fold that of sulfisoxazole, and from 1/3 to equal on a blood-level basis, but was not as potent as sulfadiazine.
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 08:59:14 GMT 2025
by
admin
on
Wed Apr 02 08:59:14 GMT 2025
|
| Record UNII |
ZZZ3BU4OA7
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C29739
Created by
admin on Wed Apr 02 08:59:14 GMT 2025 , Edited by admin on Wed Apr 02 08:59:14 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C152458
Created by
admin on Wed Apr 02 08:59:14 GMT 2025 , Edited by admin on Wed Apr 02 08:59:14 GMT 2025
|
PRIMARY | |||
|
3836
Created by
admin on Wed Apr 02 08:59:14 GMT 2025 , Edited by admin on Wed Apr 02 08:59:14 GMT 2025
|
PRIMARY | |||
|
C005744
Created by
admin on Wed Apr 02 08:59:14 GMT 2025 , Edited by admin on Wed Apr 02 08:59:14 GMT 2025
|
PRIMARY | |||
|
DTXSID80173584
Created by
admin on Wed Apr 02 08:59:14 GMT 2025 , Edited by admin on Wed Apr 02 08:59:14 GMT 2025
|
PRIMARY | |||
|
1097
Created by
admin on Wed Apr 02 08:59:14 GMT 2025 , Edited by admin on Wed Apr 02 08:59:14 GMT 2025
|
PRIMARY | |||
|
SUB10730MIG
Created by
admin on Wed Apr 02 08:59:14 GMT 2025 , Edited by admin on Wed Apr 02 08:59:14 GMT 2025
|
PRIMARY | |||
|
m944
Created by
admin on Wed Apr 02 08:59:14 GMT 2025 , Edited by admin on Wed Apr 02 08:59:14 GMT 2025
|
PRIMARY | Merck Index | ||
|
ZZZ3BU4OA7
Created by
admin on Wed Apr 02 08:59:14 GMT 2025 , Edited by admin on Wed Apr 02 08:59:14 GMT 2025
|
PRIMARY | |||
|
16132
Created by
admin on Wed Apr 02 08:59:14 GMT 2025 , Edited by admin on Wed Apr 02 08:59:14 GMT 2025
|
PRIMARY | |||
|
1984-94-7
Created by
admin on Wed Apr 02 08:59:14 GMT 2025 , Edited by admin on Wed Apr 02 08:59:14 GMT 2025
|
PRIMARY | |||
|
CHEMBL2107230
Created by
admin on Wed Apr 02 08:59:14 GMT 2025 , Edited by admin on Wed Apr 02 08:59:14 GMT 2025
|
PRIMARY | |||
|
100000083782
Created by
admin on Wed Apr 02 08:59:14 GMT 2025 , Edited by admin on Wed Apr 02 08:59:14 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
